Health & Fitness
Health and Fitness
Health and Fitness
Thu, June 3, 2010
Wed, June 2, 2010 SensiVida Medical Technologies, Inc. Enters Design and Development Agreement With Wi, Inc. to Advance Development of the Compan
HENRIETTA, NY--(Marketwire - June 2, 2010) - SensiVida Medical Technologies (
Under the agreement, Wi will provide design and prototype development for the disposable allergen delivery component of the allergy test system. The disposable allergen "cartridge" will provide allergists and other medical professionals the ability to rapidly test patients using up to 40 allergens on small areas of the patient's skin (about one square inch). In contrast, today's skin prick test is typically performed on all of the patient's back or forearms, and often produces large, uncomfortable reactions or "wheals" that take many hours to dissipate. Early clinical results using SensiVida's disposable allergen cartridge and digital sensing module show that it is totally painless, less invasive, faster, and more accurate than today's test (See [ http://www.marketwire.com/press-release/SensiVida-Medical-Technologies-Inc-Announces-Promising-Early-Human-Clinical-Results-1259527.htm ])
"We are pleased to announce this collaboration with Wi," said Jose Mir, President and CEO of SensiVida Medical Technologies. "We believe that Wi's significant expertise in the development of disposables and microfluidic devices provides critical resources that will accelerate commercialization of our novel allergy test system."
Wi will build upon SensiVida's disposable allergen cartridge technology using design-for-manufacturing (DFM) disciplines while providing access to high volume manufacturing partners. In addition to developing preferred designs and prototypes, Wi's pilot manufacturing capabilities will help reduce SensiVida's cycle time to reach FDA clinicals and product launch.
About Wi, Inc.
Wi, Inc. ([ www.wiinc.net ]) is a vertically integrated product development firm specializing in assisting clients in the commercialization of in vitro diagnostics devices from concept to pilot build. Wi's team of scientists and engineers are educated in the clinical applications of the markets they serve and dedicated to advancing medical science through point-of-care diagnostics and lifesaving therapies that ultimately reduce the cost of healthcare.
About SensiVida Medical Technologies, Inc.
SensiVida is a developer and provider of minimally invasive diagnostic devices with proprietary, microsystems-based technology that automates bio-sensing and data acquisition while minimizing patient discomfort. The Company's optical-digital platform technology addresses a number of multi-billion dollar market opportunities: allergy testing, pain-free automated glucose monitors, blood coagulation testing, TB testing, cholesterol monitoring, and more.
SensiVida has an exclusive worldwide license to nine pending patents. In addition to the SensiVida allergy test, the product pipeline, based on the same microsystem and image processing technology, includes a portable glucose monitor. This device consists of a patch or chip having multiple, individually addressable sensors that are activated in accordance with the patient's test schedule, automatically recording the patient's glucose level without pain, bio-fouling or clogging. For more information about Sensivida, please visit [ www.Sensividamedtech.com ]
Forward Looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Quarterly Report on Form 10Q and related 8-K filings.
